About in8bio inc - INAB
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
INAB At a Glance
IN8bio, Inc.
350 5th Avenue
New York, New York 10118
| Phone | 1-646-600-6438 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -19,440,000.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.829 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.811 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.198 |
INAB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,143,529.412 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INAB Liquidity
| Current Ratio | 8.82 |
| Quick Ratio | 8.82 |
| Cash Ratio | 8.571 |
INAB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -71.643 |
| Return on Equity | -92.492 |
| Return on Total Capital | -64.074 |
| Return on Invested Capital | -82.755 |
INAB Capital Structure
| Total Debt to Total Equity | 10.095 |
| Total Debt to Total Capital | 9.169 |
| Total Debt to Total Assets | 8.618 |
| Long-Term Debt to Equity | 5.672 |
| Long-Term Debt to Total Capital | 5.152 |